Chocolate tested for kidney effects – but Don't get excited yet

NCT ID NCT05755217

Completed Knowledge-focused Sponsor: Gregoire Wuerzner; MD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 4 times

Summary

This study looks at whether eating a single dose of dark chocolate (70% cocoa) changes blood flow to the kidneys and blood pressure, compared to white chocolate. Researchers will use ultrasound to measure kidney blood flow two hours after eating. The study includes 32 people: healthy volunteers and those with mild-to-moderate chronic kidney disease. It's a small, early-stage study that aims to gather basic knowledge, not to prove any treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dark chocolate (70% cocoa) and white chocolate (4% cocoa)
What this could lead to: If it works, this could help us understand whether dark chocolate has any short-term benefits for kidney function and blood pressure.
What could go wrong: This is a very small, early study (32 people) looking only at immediate effects after a single dose. It won't prove any long-term health benefits or risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOCOLATE CONSUMPTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOCOLATE CONSUMPTION

Contacts and locations

Locations

Department of Nephrology, Centre Hospitalier Universitaire Vaudois

Lausanne, Canton of Vaud, 1011, Switzerland
University Hospital of Lausanne (CHUV)

Lausanne, Canton of Vaud, 1011, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.